Bavarian Nordic reports positive data from Phase II Covid-19 booster trial
In the trial, vaccination with ABNCoV2 led to a substantial improvement in neutralising antibodies against the Omicron variant.

In the trial, vaccination with ABNCoV2 led to a substantial improvement in neutralising antibodies against the Omicron variant.
LEO Pharma will use Veeva’s CDMS, eConsent, eTMF, CTMS, Site Connect, ePRO, Virtual Visits, and eSource products.
The trial will enrol a total of up to 210 healthy adults in Germany who will receive a single or…
The vaccine showed favourable tolerability and safety profile, as well as generated high antibody titres against SARS-CoV-2.
Novo Nordisk has announced positive headline results from Phase IIIb SUSTAIN FORTE trial of once-weekly semaglutide 1mg versus 2mg dose…
Novo Nordisk is set to resume the Phase III explorer 6, 7 and 8 clinical trials of concizumab as a…
Biopharmaceutical firm Orphazyme has reported positive interim results from an open-label extension study of a Phase II/III clinical trial of…
Bavarian Nordic has reported data from the Phase III efficacy study of MVA-BN (Jynneos) vaccine, which is designed to prevent…
Thank you for subscribing to Clinical Trials Arena